Registry data reveals safety of COVID-19First identified in 2019 in Wuhan, China, Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It has spread globally, resulting in the 2019–20 coronavirus pandemic.”>COVID-19 vaccines in people with rheumatic and musculoskeletal diseases.
COVID-19 is the disease caused by infection with the SARS-CoV-2Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the official name of the virus strain that causes coronavirus disease (COVID-19). Previous to this name being adopted, it was commonly referred to as the 2019 novel coronavirus (2019-nCoV), the Wuhan coronavirus, or the Wuhan virus.”>SARS-CoV-2 virus. Since it emerged at the end of 2019, the virus has caused a global pandemic. In February 2021, EULAR, the European Alliance of Associations for Rheumatology, launched COVAX – a physician-reported registry to collect information about COVID vaccination in people with both inflammatory and non-inflammatory RMDs. Rheumatologists in EULAR-affiliated countries were asked to report as many cases as possible of people with RMDs who had received a COVID vaccine, whether or not they had experienced side effects.
From February to July 2021, information was collected for 5,121 people with different types of RMD who had received at least one dose of a COVID vaccine. The most common inflammatory RMDs were rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. The most common non-inflammatory RMDs were osteoarthritis and osteoporosis. Among people with inflammatory RMDs, 54% were taking a conventional synthetic disease-modifying antirheumatic drug (csDMARD), 42% were on biological DMARDs (bDMARDs), and 35% were taking immunosuppressant medicines for their RMD (e.g., glucocorticoids, mycophenolate, azathioprine).
The results from COVAX show that the majority of people with inflammatory RMDs tolerate their COVID vaccine well – with no difference in safety profile to that seen in the general population or people with non-inflammatory RMDs. The most common side effects were short-lived reactions to the injection. One of the reasons for asking additional safety questions in people with inflammatory RMDs is the concern that the vaccine could cause a disease flare. In this study, only 4.4% of people experienced a flare after having their COVID vaccine, and only 0.6% were classed as severe. The majority of people (over 98%) were able to continue on their normal medication with no changes. The study also found there was a low rate of COVID-19 infections in people with RMDs once they were fully vaccinated.
These are valuable findings which will support discussions about the safety and benefit/risk ratio of COVID vaccination for people with RMDs. The information will also be useful for the development of new and updated recommendations.
Reference: “Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry” by Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F Mateu, Kimme L Hyrich, Laure Gossec, Loreto Carmona, Ana Rodrigues, Bernd Raffeiner, Catia Duarte, Eric Hachulla, Eric Veillard, Eva Strakova, Gerd R Burmester, Gözde Kübra Yardimci, Jose A Gomez-Puerta, Julija Zepa, Lianne Kearsley-Fleet, Ludovic Trefond, Maria Cunha, Marta Mosca, Martina Cornalba, Martin Soubrier, Nicolas Roux, Olivier Brocq, Patrick Durez, Richard Conway, Tiphaine Goulenok, Johannes WJ Bijlsma, Iain B McInnes and Xavier Mariette, 31 December 2021, Annals of the Rheumatic Diseases.